Docosahexanoic Acid Supplement ( DrugBank: Docosahexanoic Acid )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00924547 (ClinicalTrials.gov) | November 2013 | 17/6/2009 | Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis | Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis: Effects on Exhaled Pro-inflammatory Isoprostanes and Analysis of Its Esterification Sites in Plasma | Cystic Fibrosis | Dietary Supplement: Docosahexanoic Acid Supplement;Dietary Supplement: Placebo | Vanderbilt University | NULL | Completed | 6 Years | N/A | Both | 17 | Phase 2 | United States |